key: cord-0857952-y3yq12tf
authors: Zia, Komal; Khan, Salman Ali; Ashraf, Sajda; Nur-e-Alam, Mohammad; Ahmed, Sarfaraz; Ul-Haq, Zaheer
title: Probing CAS database As Prospective Antiviral Agents Against SARS-CoV-2 Main Protease
date: 2021-01-19
journal: J Mol Struct
DOI: 10.1016/j.molstruc.2021.129953
sha: 74816295fdaaca25d9007a7ce745cea247780f6b
doc_id: 857952
cord_uid: y3yq12tf

The pandemic of COVID-19 has an unprecedented impact on global health and economy. The novel SARS-CoV-2 is recognized as the etiological agent of current outbreak. Because of its contagious human-to-human transmission, it is an utmost global health emergency at present. To mitigate this threat many scientists and researchers are racing to develop antiviral therapy against the virus. Unfortunately, to date no vaccine or antiviral therapeutic is approved thus there is an urgent need to discover antiviral agent to help the individual who are at high risk. Virus main protease or chymotrypsin-like protease plays a pivotal role in virus replication and transcription; thus, it is considered as an attractive drug target to combat the COVID-19. In this study, multistep structure based virtual screening of CAS antiviral database is performed for the identification of potent and effective small molecule inhibitors against chymotrypsin-like protease of SARS-CoV-2. Consensus scoring strategy combine with flexible docking is used to extract potential hits. As a result of extensive virtual screening, 4 hits were shortlisted for MD simulation to study their stability and dynamic behavior. Insight binding modes demonstrated that the selected hits stabilized inside the binding pocket of the target protein and exhibit complementarity with the active site residues. Our study provides compounds for further in vitro and in vivo studies against SARS-CoV-2.

The main protease of SARS-CoV-2 exhibit high structural and sequence homology to 3CLpro of SARS-CoV (96% sequence identity) and their sequence alignment indicate only 12 and domain-II (100−182). The thiol group of Cys145 acts as nucleophile in the proteolytic process. A long loop region is connected the catalytic domains to the C-terminal domain-III (residues 198−303) composed of five antiparallel α-helical [18] .

The M pro exist catalytically active in dimeric state and arranged perpendicular to each another.

The dimeric form has a unique substrate binding preference for glutamine residue at the P1 site (Leu-Gln ↓ Ser, Ala, Gly), that distinguish it from other closely related proteases in host, suggesting that it is feasible to achieve high selectivity by targeting viral M pro . The dimerization of two M pro protomer, facilitate the formation of substrate-binding cleft in which conformationally distinct solvent-exposed His41 and Cys145 in the cleft act independently [19] .

Scientists around the world are racing to discover the drug or vaccine against COVID-19. In this regard extensive theoretical and experimental work has been done [20] [21] [22] [23] [24] [25] [26] [27] . Many antiviral drugs are also in clinical trials against SARS-CoV-2, yet no vaccine or antiviral agent against this deadly virus is discovered. Herein, we perform a structure based virtual screening of CAS COVID-19 database with potential antiviral properties to identify prototypic inhibitors against the SARS-CoV-2 M pro target. The approach involved score-based virtual screening, molecular dynamics simulations and binding free energy calculations. Based on consensus scoring strategy 

The Chemical Abstract Services released an open source CAS COVID-19 database, containing ~50,000 potential antiviral candidates. The dataset was downloaded (https://www.cas.org/covid-19-antiviral-compounds-dataset) and the redundant compounds were checked by their CAS number and eliminated. Afterwards, the database was converted from 2D to 3D followed by geometry optimization using WASH module implemented in MOE. Subsequently, hydrogens were added followed by energy minimization using MMFF94 force field and single low energy conformation was generated with original state of chirality and ionization states for each compound. Considering the larger size of binding pocket of 3CLPro and high molecular weight of effetive antiviral drugs against coronaviruses main protease (e.g. Saquinavir, Darunavir, Lopinavir etc), compounds with molecular weight upto 715g/mol were selected. The final database consisting of 35,000 compounds, was saved in mdb format for screening.

Structure-based virtual screening was carried out using the x-ray crystal structure of chymotrypsin-like protease (PDB-ID 6LU7, resolution 2.16 Å) [18] of SARS-CoV-2 bound to peptide like inhibitor (N3). Co-crystalized artifacts such as missing atoms and loops were modeled by Structure Preparation module implemented in MOE 2019.01. All the crystallized water molecules were deleted, and the crystal structure was subjected to protonation and energy minimization using Amber99 force field in MOE. A docking grid of 6 Å was generated, centered on the protein active site by selecting the atoms of co-crystalized ligand, N3.

Prepared CAS antiviral database containing 35,000 compounds were docked into the define grid center on the co-crystalized ligand. During docking the receptor kept flexible and Triangular

Matcher was used as placement method, which is the most efficient method for well-defined Protein-ligand interaction fingerprint (PLIF) module implemented in MOE was used to analyzed all interactions between protein and the selected compounds [28] . The top 78 compounds were selected and subjected to protein ligand interaction profile (PLIP) for their binding interactions.

As a result of this analysis compounds were shortlisted on the basic of interactions with hotspot residues in addition to catalytic dyad; Phe140, Leu141, Asn142, Gly143, Ser144, Met165 and

Gln189. Finally, 4 hits, containing tetrahydrofuran and purine ring as chemical scaffold, obtained from structure-based virtual screening were subjected to molecular dynamics simulation. The schematic representation of stepwise screening strategy shown in Figure 2 . 

All the simulations were carried out using GROMACS version 2018 [29] on GPU. The topological parameters of protein structure were processed by GROMOS 57a7 force field [30] while Automated Topological Builder was used for the parameterization of all the ligands. All the complex structures were solvated using single point charge water model by placing into a cubic water box and keeping the distance of 1.0 nm from the edge of the water box with periodic boundary condition. Subsequently, the systems were neutralized by the addition of counter ions.

Prepared systems were minimized to remove the bad contacts and to correct the geometry by using steepest descent algorithm with maximum force < 1000 kJ mol−1 nm−1. The electrostatic interactions were treated by Particle Mesh Ewald algorithm with a cut-off of 1.2 nm while LINCS algorithm was used to constrained the bond length. To obtain further convergence, the minimized systems were equilibrated for 500 ps in an NVT ensemble followed by NPT ensemble. During equilibration, pressure and volume were maintained by using isobaricisothermal algorithm. Finally, the production run of 100ns was carried out and coordinates along with their energies were saved after every 10 ps in output trajectory file. The convergence for all the simulated systems were analyzed by RMSD RMSF, RoG, and hydrogen bond contacts using GROMACS and VMD [31] . Moreover, the Coulombic potentials within R-coulomb (Coul-SR) and the short-range Lennard-Jones energies (LJ-SR) were calculated using the g_energy program available in GROMACS, extracting the information from .edr files produced during the MD simulations.

The recent coronavirus pandemic demands the immediate discovery of therapeutic agent to cure and protect the people who are suffering from the COVID-19. In order to combat the spreading pandemic and to accelerate the discovery of antiviral agent against SARS-CoV-2, structure- It has been reported that combining different scoring functions or consensus scoring leads to a higher probability of enrichment of true positives. In this study, mainly focus on empirical scoring functions implemented in MOE to provide a real feature of combination to extract potential hit compounds. In this regard, the prepared database consists of 35,000 compounds was docked into the define grid using different scoring function including London dG, GBVI/WSA dG, ASE, Affinity dG and Alpha HB with Triangular Matcher as placement method (Table 1) .

Total 34,372 compounds were correctly docked into the defined pocket, and the docked poses of each candidate were sort out from highest to lowest docking score. Afterwards, the compounds were shortlisted by employing consensus scoring strategy [32, 33] which led the selection of top 10% of data containing compounds from each scoring function and the top-scored ~3400 compounds were considered for further screening. Thus, the outcome of the virtual screening was inspected in terms of (i) docking accuracy i.e., rmsd to known solutions, (ii 

The molecular dynamics simulation provides the information about the stability of the proteinligand complexes in a time dependent manner. In this study, we employed 100ns simulation of 4 compounds: SKS-01, SKS-02, SKS-03 and SKS-04 in complex with 3CLPro of SARS-CoV-2.

The stability of these ligands within the active site of target protein was analyzed by plotting root mean square deviation (RMSD) of the backbone atoms and root mean square fluctuation (RMSF) of amino acid residues. In order to determine the compactness of the protein upon binding of the ligands, radius of gyration (RoG) was also calculated.

MD trajectories were analyzed to ensure the binding stability of all the four protein-ligand complexes by calculating the deviation of backbone carbon atom. All the systems showed inconsiderable fluctuation with the deviation of less than 0.4nm during the whole simulation. 

In order to determine the compactness or folding of the target protein during 100ns simulation, radius of gyration was calculated. Gyration score for all the systems oscillated between 2.15nm to 2.30nm ( Figure 5 ). The average gyration score of Apo, SKS-01, SKS-02, SKS-03 and SKS-04 was found to be 2.20 ± 0.04, 2.21 ± 0.02, 2.24 ± 0.01, 2.23 ± 0.01 and 2.21 ± 0.01 respectively.

RoG analysis suggested that all the simulated systems more or less showed similar degree of compactness. 

Comprehensive interactions profile before and after MD simulation, between the selected compounds and the important binding residues of target protein is presented in Table 2 Upon examining the MD trajectories, SKS-01 found to form six hydrogen bonds contacts with significant persistence ( Figure 6A ). Oxygen of benzoyl oxycarbonyl moiety in the ligand mediate hydrogen bond with the backbone amide of Met165 (Table 2) 

The SARS-CoV-2 chymotrypsin like protease, plays a pivotal role in the virus maturation and life cycle, therefore it is considered as an attractive drug target to combat COVID-19. Due to lack of antiviral therapy and vaccine under development, the identification of chemical probe inhibitors of 3CLPro that can potentially be optimized as therapeutic agent seems to be highly desirable. In the present study structure-based virtual screening of CAS antiviral database containing ~50,000 compounds was carried against 3CLPro of SARS-CoV-2. Virtual screening campaign utilize the consensus scoring strategy in combination with flexible docking which led the extraction of potential hit compounds. The extracted compounds were further subjected to molecular interactions analysis. In the successive screening, 4 hits were shortlisted and subjected to dynamic study. The results of MD simulation suggested that all the selected compounds significantly stabilize the protein structure and have encouraging potential to inhibit the protein activity. We believe that our findings provide suitable chemical candidates for further detailed in vitro and in vivo analyses.

Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Ul-Haq, Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach

World Health Organization Declared a Pandemic Public Health Menace: A Systematic Review of the Coronavirus Disease

Potential maternal and infant outcomes from coronavirus 2019-NCOV (SARS-CoV-2) infecting pregnant women: Lessons from SARS, MERS, and other human coronavirus infections

Zoonotic origins of human coronaviruses

Does SARS-CoV-2 has a longer incubation period than SARS and MERS?

Strategic assessment of COVID-19 pandemic in Bangladesh: comparative lockdown scenario analysis, public perception, and management for sustainability

Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India

Understanding COVID-19 transmission, health impacts and mitigation: timely social distancing is the key

Coronaviruses: An overview of their replication and pathogenesis

The first 75 days of novel coronavirus (SARS-CoV-2) outbreak: Recent advances, prevention, and treatment

López-Cortés, Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review

A new coronavirus associated with human respiratory disease in China

Emerging coronaviruses: genome structure, replication, and pathogenesis

Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses

Coronavirus main proteinase: target for antiviral drug therapy

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

through a drug-target interaction deep learning model

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease

Interaction fingerprints and their applications to identify hot spots

Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers

Definition and testing of the GROMOS force-field versions 54A7 and 54B7

VMD: Visual molecular dynamics

The use of consensus scoring in ligand-based virtual screening

Consensus queries in ligand-based virtual screening experiments

The authors also thank the Deanship of Scientific Research at King Saud University, Saudi Arabia for funding through the research group project no. RGP-1438-043. 

The authors declare no competing financial interests.